Comparison of clinical review and regulation for biologics and chemical drugs of FDA:a case study of type 2 diabetes mellitus

LI Da-wei,DONG Ke,YAO Li-xin,ZHENG Qiang
2013-01-01
Abstract:Objective:To study FDA's approval criteria,considerations and post approval regulatory actions of biologics and chemical drugs for type 2 diabetes mellitus.Methods:Analyze the drug approval packages and other public information with respect to clinical reviews,labels and revisions,post-approval requirements and commitments,and regulatory actions.Results:The review criteria for biologics and chemical drugs for type 2 diabetes mellitus are basically consistent.Conclusion:No remarkable difference is observed in the review consideration and post approval regulatory actions between biologics and chemical drugs for type 2 diabetes mellitus.With more post-marketing experience and other considerations,FDA has updated its review criteria and regulatory considerations,and provided industry guidances accordingly.
What problem does this paper attempt to address?